Zoster Vaccine Has Dementia-Preventing or Delaying Effect
By Elana Gotkine HealthDay Reporter
THURSDAY, April 3, 2025 -- Zoster vaccination seems to have a dementia-preventing or dementia-delaying effect, according to a study published online April 2 in Nature.
Markus Eyting, Ph.D., from Stanford University in California, and colleagues examined the effect of live-attenuated herpes zoster vaccination on the occurrence of dementia diagnosis. Causal evidence was provided using data from Wales, where eligibility for the zoster vaccine was determined based on an individual's exact date of birth, with those born before Sept. 2, 1933, being ineligible for life and those born on or after Sept. 2, 1933, being eligible for at least one year to receive the vaccine.
The researchers observed an increase in the percentage of adults who received the vaccine, from 0.01 percent among those who were one week too old to receive the vaccine to 47.2 percent among those who were one week younger. Receipt of zoster vaccine reduced the probability of a new dementia diagnosis during a seven-year follow-up period by 3.5 percentage points, corresponding to a relative reduction of 20.0 percent. A stronger protective effect was seen for women than men. The findings were confirmed in England and Wales's combined population using death certificates, with dementia as the primary cause of death as the outcome.
"By taking advantage of the fact that the unique way in which the zoster vaccine was rolled out in Wales constitutes a natural experiment, and examining each possible remaining source of bias, our study provides evidence that is more likely to be causal in nature than the existing, exclusively associational, evidence on this topic," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted April 2025
Read this next
GLP-1 Receptor Agonists Tied to Decrease in T2DM-Related Dementia Risk
WEDNESDAY, July 23, 2025 -- Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with reduced type 2 diabetes mellitus (T2DM)-related dementia risk compared with...
Risk for Dementia, Ischemic Stroke, Mortality Lower With GLP-1 Receptor Agonists in T2D, Obesity
TUESDAY, July 22, 2025 -- For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke...
35 Percent of Eligible Children Receive RSV Prophylaxis With Nirsevimab
TUESDAY, July 22, 2025 -- Despite near universal availability of nirsevimab, only 35 percent of eligible children receive nirsevimab for respiratory syncytial virus (RSV)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.